// App-Quantinova.ai

80 : Association of co-occurring gene alterations and clinical activity of rucaparib in patients with BRCA1 or BRCA2 mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Wassim Abida

Principal Investigators

  • David Campbell

  • Jeremy David Shapiro

  • Alan Haruo Bryce

  • Raymond S. McDermott

  • Brieuc Sautois

  • Nicholas J. Vogelzang

  • Richard M Bambury

  • Eric Voog

  • Jingsong Zhang

  • Josep M. Piulats

  • Charles J. Ryan

  • Axel Stuart Merseburger

  • Karim Fizazi

  • Darrin Despain

  • Andrea Loehr

  • Melanie Dowson

  • Tony Golsorkhi

  • Simon Chowdhury

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • The University of Chicago Medical Center, Chicago, IL

  • Barwon Health, University Hospital Geelong,Victoria,Australia

  • Cabrini Hospital, Malvern, VIC, Australia

  • Mayo Clinic, Phoenix, AZ

  • The Adelaide and Meath Hospital, Dublin Incorporating the National Childrens Hospital, Dublin, Ireland

  • University Hospital of Liège, CHU Sart-Tilman, Liège, Belgium

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV

  • Cork University Hospital, Cork, Ireland

  • Clinique Victor Hugo - Centre Jean Bernard, Le Mans, France

  • Moffitt Cancer Center, Tampa, FL

  • ICO Institut Catala d'Oncologia, Barcelona, Spain

  • University of Minnesota, Minneapolis, MN

  • Lubeck University Hospital, Lubeck, Germany

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

  • Clovis Oncology, Inc., Boulder, CO

  • Clovis Oncology UK, Ltd, Cambridge, CO, United Kingdom

  • Guys, Kings and St. Thomas Hospitals, and Sarah Cannon Research Institute, London, United Kingdom

Locations

  • United States

  • Australia

  • Ireland

  • Belgium

  • France

  • Spain

  • Germany

  • United Kingdom

Companies

  • Clovis Oncology, Inc

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic castration-resistant prostate cancer

  • Solid malignancies

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Breast cancer type 2 susceptibility protein

  • Prostate specific antigen

  • BRCA mutation

Drug/Treatment

  • Rucaparib

  • Androgen Tear

  • Methadone hydrochloride

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02952534

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved